{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:00:10Z","timestamp":1792807210023,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40257-023-00810-7","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T07:02:08Z","timestamp":1692946928000},"page":"127-138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post\u00a0Hoc Analysis of JADE MONO-2"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-1822","authenticated-orcid":false,"given":"Gil","family":"Yosipovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-1861","authenticated-orcid":false,"given":"Luz","family":"Fonacier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-9925","authenticated-orcid":false,"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-0493","authenticated-orcid":false,"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0082-6545","authenticated-orcid":false,"given":"Andrew G.","family":"Bushmakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-0748","authenticated-orcid":false,"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-6571","authenticated-orcid":false,"given":"Claire","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1338-132X","authenticated-orcid":false,"given":"Gary","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8058-1922","authenticated-orcid":false,"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-4676","authenticated-orcid":false,"given":"Marco","family":"DiBonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1426-9919","authenticated-orcid":false,"given":"Daniela E.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"issue":"5","key":"810_CR1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","volume":"132","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"1 Pt 1","key":"810_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0091-6749(99)70536-1","volume":"103","author":"H Williams","year":"1999","unstructured":"Williams H, Robertson C, Stewart A, A\u00eft-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103(1 Pt 1):125\u201338.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"810_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583\u201390.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"810_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"810_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"810_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393.","journal-title":"Allergy"},{"issue":"2","key":"810_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","volume":"138","author":"T Werfel","year":"2016","unstructured":"Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336\u201349.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"810_CR8","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/jdv.16003","volume":"34","author":"M de Bruin-Weller","year":"2020","unstructured":"de Bruin-Weller M, Gadkari A, Auziere S, Simpson EL, Puig L, Barbarot S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026\u201336.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"810_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.0025","volume":"173","author":"FD Ramirez","year":"2019","unstructured":"Ramirez FD, Chen S, Langan SM, Prather AA, McCulloch CE, Kidd SA, et al. Association of atopic dermatitis with sleep quality in children. JAMA Pediatr. 2019;173(5): e190025.","journal-title":"JAMA Pediatr"},{"issue":"1","key":"810_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/jid.2014.325","volume":"135","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56\u201366.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"810_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.smrv.2010.03.003","volume":"14","author":"R Sack","year":"2010","unstructured":"Sack R, Hanifin J. Scratching below the surface of sleep and itch. Sleep Med Rev. 2010;14(6):349\u201350.","journal-title":"Sleep Med Rev"},{"issue":"5","key":"810_CR12","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jaci.2015.08.028","volume":"136","author":"AB Fishbein","year":"2015","unstructured":"Fishbein AB, Vitaterna O, Haugh IM, Bavishi AA, Zee PC, Turek FW, et al. Nocturnal eczema: review of sleep and circadian rhythms in children with atopic dermatitis and future research directions. J Allergy Clin Immunol. 2015;136(5):1170\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"810_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13555-020-00459-8","volume":"11","author":"G Girolomoni","year":"2020","unstructured":"Girolomoni G, Luger T, Nosbaum A, Gruben D, Romero W, Llamado LJ, et al. The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey. Dermatol Ther (Heidelb). 2020;11(1):117\u201330.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"810_CR14","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1080\/03007995.2016.1195733","volume":"32","author":"J Whiteley","year":"2016","unstructured":"Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1645\u201351.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"810_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2017.04.019","volume":"77","author":"L Eckert","year":"2017","unstructured":"Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"810_CR16","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/1346-8138.12220","volume":"40","author":"C Yano","year":"2013","unstructured":"Yano C, Saeki H, Ishiji T, Ishiuji Y, Sato J, Tofuku Y, et al. Impact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitis. J Dermatol. 2013;40(9):736\u20139.","journal-title":"J Dermatol"},{"key":"810_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.644760","volume":"8","author":"FJ Legat","year":"2021","unstructured":"Legat FJ. Itch in atopic dermatitis\u2014what is new? Front Med (Lausanne). 2021;8:644760.","journal-title":"Front Med (Lausanne)."},{"issue":"10247","key":"810_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"1","key":"810_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2021.07.078","volume":"86","author":"N Sutaria","year":"2022","unstructured":"Sutaria N, Adawi W, Goldberg R, Roh YS, Choi J, Kwatra SG. Itch: pathogenesis and treatment. J Am Acad Dermatol. 2022;86(1):17\u201334.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"810_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1390","volume":"11","author":"SG Kwatra","year":"2022","unstructured":"Kwatra SG, Misery L, Clibborn C, Steinhoff M. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin Transl Immunol. 2022;11(5): e1390.","journal-title":"Clin Transl Immunol"},{"issue":"5","key":"810_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/jdv.18081","volume":"36","author":"L Misery","year":"2022","unstructured":"Misery L. Sleep disturbance and psoriasis. J Eur Acad Dermatol Venereol. 2022;36(5):633.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"810_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/alr.22607","volume":"10","author":"FL Cheng","year":"2020","unstructured":"Cheng FL, An YF, Han ZQ, Li C, Li ZQ, Yang PC, et al. Period2 gene regulates diurnal changes of nasal symptoms in an allergic rhinitis mouse model. Int Forum Allergy Rhinol. 2020;10(11):1236\u201348.","journal-title":"Int Forum Allergy Rhinol."},{"issue":"4","key":"810_CR23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaci.2018.08.005","volume":"142","author":"YS Chang","year":"2018","unstructured":"Chang YS, Chiang BL. Sleep disorders and atopic dermatitis: A 2-way street? J Allergy Clin Immunol. 2018;142(4):1033\u201340.","journal-title":"J Allergy Clin Immunol"},{"key":"810_CR24","unstructured":"Cibinqo 100 mg film-coated tablets. Summary of product characteristics. Kent: Pfizer Limited; 2021. (09\/10\/2021)."},{"key":"810_CR25","unstructured":"Japan's MHLW approves Pfizer\u2019s Cibinqo\u00ae (abroctinib) for adults and adolescents with moderate to severe atopic dermatitis. New York: Pfizer, Inc.; 2021."},{"key":"810_CR26","unstructured":"European Medicines Agency. Cibinqo\u00ae (abrocitinib). Summary of Product Characteristics (SmPC). Belgium: Pfizer Europe MA EEIG; 2021. (12\/2021)."},{"key":"810_CR27","unstructured":"Cibinqo (abrocitinib) tablets, for oral use. Prescribing information. New York: Pfizer Inc; 2023. (02\/2023)."},{"issue":"12","key":"810_CR28","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"810_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"8","key":"810_CR30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"810_CR31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI. Abrocitinib versus placebo and dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"10","key":"810_CR32","first-page":"1165","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: results from JADE TEEN. J Dermatol. 2021;157(10):1165\u201373.","journal-title":"J Dermatol"},{"issue":"1","key":"810_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312.","journal-title":"J Am Acad Dermatol"},{"key":"810_CR34","unstructured":"Thaci T, Bieber T, Simpson EL, Silverberg JI, Paul C, Sinclair R. A phase 3 study to investigate the efficacy and safety of abrocitinib and dupilumab in comparison with placebo in adults with moderate-to-severe atopic dermatitis. 29th EADV Congress. Virtual; 2020."},{"issue":"2, Supplement","key":"810_CR35","doi-asserted-by":"publisher","first-page":"AB34","DOI":"10.1016\/j.jaci.2020.12.158","volume":"147","author":"G Yosipovitch","year":"2021","unstructured":"Yosipovitch G, Fonacier L, St\u00e4nder S, Su J, Gooderham M, Szepietowski J, et al. Pruritus, sleep, and productivity: a post hoc analysis of abrocitinib versus placebo in patients with moderate-to-severe atopic dermatitis (AD) from JADE MONO-2. J Allergy Clin Immunol. 2021;147(2, Supplement):AB34.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"810_CR36","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139.","journal-title":"Br J Dermatol"},{"key":"810_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/9781119513469","volume-title":"Applied longitudinal analysis","author":"GM Fitzmaurice","year":"2011","unstructured":"Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. 2nd ed. Hoboken: Wiley; 2011.","edition":"2"},{"key":"810_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/9781119376354","volume-title":"A practical approach to quantitative validation of patient-reported outcomes: a simulation-based guide using SAS","author":"AG Bushmakin","year":"2022","unstructured":"Bushmakin AG, Cappelleri JC. A practical approach to quantitative validation of patient-reported outcomes: a simulation-based guide using SAS. Hoboken: Wiley; 2022."},{"key":"810_CR39","doi-asserted-by":"publisher","DOI":"10.4135\/9781412984966","volume-title":"Mediation analysis","author":"D Iacobucci","year":"2008","unstructured":"Iacobucci D. Mediation analysis. Thousand Oaks: SAGE Publications, Inc.; 2008."},{"issue":"6","key":"810_CR40","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2340\/00015555-1159","volume":"91","author":"U Matterne","year":"2011","unstructured":"Matterne U, Apfelbacher CJ, Loerbroks A, Schwarzer T, Buttner M, Ofenloch R, et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm Venereol. 2011;91(6):674\u20139.","journal-title":"Acta Derm Venereol"},{"key":"810_CR41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1196\/annals.1308.032","volume":"1021","author":"MA Carskadon","year":"2004","unstructured":"Carskadon MA, Acebo C, Jenni OG. Regulation of adolescent sleep: implications for behavior. Ann N Y Acad Sci. 2004;1021:276\u201391.","journal-title":"Ann N Y Acad Sci"},{"key":"810_CR42","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neubiorev.2021.03.021","volume":"126","author":"AJ Fuligni","year":"2021","unstructured":"Fuligni AJ, Chiang JJ, Tottenham N. Sleep disturbance and the long-term impact of early adversity. Neurosci Biobehav Rev. 2021;126:304\u201313.","journal-title":"Neurosci Biobehav Rev."},{"key":"810_CR43","volume-title":"Sleep disorders and sleep deprivation: an unmet public health problem","author":"Institute of Medicine Committee on Sleep Medicine and Research","year":"2006","unstructured":"Institute of Medicine Committee on Sleep Medicine and Research. The National Academies Collection: reports funded by National Institutes of Health. In: Colten HR, Altevogt BM, editors. Sleep disorders and sleep deprivation: an unmet public health problem. Washington: National Academies Press (US) National Academy of Sciences; 2006."},{"issue":"3","key":"810_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/ijms17030425","volume":"17","author":"MJ Lavery","year":"2016","unstructured":"Lavery MJ, Stull C, Kinney MO, Yosipovitch G. Nocturnal pruritus: the battle for a peaceful night\u2019s sleep. Int J Mol Sci. 2016;17(3):425.","journal-title":"Int J Mol Sci"},{"key":"810_CR45","doi-asserted-by":"publisher","DOI":"10.1201\/b16139","volume-title":"Patient-reported outcomes: measurement, implementation and interpretation","author":"JC Cappelleri","year":"2013","unstructured":"Cappelleri JC, Zou KH, Bushmakin AG, Ma J, Alemayehu D, Symonds T. Patient-reported outcomes: measurement, implementation and interpretation. Chapman and Hall\/CRC Press; 2013."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00810-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00810-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00810-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T19:18:20Z","timestamp":1705605500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00810-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00810-7","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"20 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gil Yosipovitch is a consultant and advisor for Cara Therapeutics, Eli Lilly, Escient, Galderma, GlaxoSmithKline, Kiniksa, LEO Pharma, Novartis, Pfizer Inc., Regeneron, Sanofi, Trevi Therapeutics, and Vifor and a principal investigator for Arcutis, Celldex, Eli Lilly, Escient, Galderma, Kiniksa, LEO Pharma, Novartis, Pfizer Inc., and Sanofi Regeneron. Melinda J. Gooderham has received grants, personal fees, honoraria, and\/or nonfinancial support from AbbVie, Amgen, AkrosPharma, AnaptysBio, Arcutis, ASLAN Pharmaceuticals, Bausch Health (Valeant), Bristol Myers Squibb, Boehringer-Ingelheim, Celgene, Dermavant Sciences, Dermira, Eli Lilly, Galderma, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, Merck, Novartis, Pfizer Inc., Roche, Sanofi Genzyme, Regeneron, Sun Pharma, and UCB. Sonja St\u00e4nder is a principal investigator for Almirall, Dermasence, Galderma, Kiniksa, LEO Pharma, Menlo Therapeutics, Novartis, Sanofi, and Trevi Therapeutics; a member of scientific advisory boards for Beiersdorf, Celgene, Galderma, Kiniksa, Pfizer, and Trevi Therapeutics; and a consultant for Bellus Health, Galderma, Novartis, Sanofi, and Vifor. Luz Fonacier received research grants (made to NYU Langone Hospital-LI) from AstraZeneca, Pfizer, Regeneron, and Shire and was a consultant and advisor for AbbVie, Eli Lilly, Pfizer, and Regeneron. Jacek C. Szepietowski has been a consultant\/advisory board member for LEO Pharma, Novartis, Sanofi\u00a0Genzyme, Trevi, and Viofor; a speaker for AbbVie, LEO Pharma, Novartis, Sanofi\u00a0Genzyme, and Sunfarm; and an investigator for AbbVie, Bristol Myers Squibb, Galapagos, Galderma, Helm, Incyte, InfaRX, Janssen-Cilag, Novartis, Pfizer, Regeneron, UCB, and Trevi. Mette Deleuran has been a principal investigator in clinical trials and an advisory board member and\/or speaker for AbbVie, ASLAN, Arena Pharmaceuticals, Eli Lilly, Incyte, La Roche Posay, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron, and Sanofi\u00a0Genzyme. Giampiero Girolomoni has been principal investigator in clinical trials sponsored by and\/or has received personal fees from AbbVie, Almirall, Amgen, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Fresenius Kabi, Genzyme, LEO Pharma, Menlo Therapeutics, Novartis, OM Pharma, Pfizer, Regeneron, Samsung Bioepis, and Sanofi. John Su has received grants\/research funding for his role as an investigator for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Galderma, Janssen, Novartis, Pfizer Inc., Pierre Fabre, and Sanofi; has received honoraria for serving on advisory boards for Eli Lilly, GSK, Janssen, LEO Pharma, L\u2019Or\u00e9al, Novartis, Pfizer Inc., and Sanofi; and has received honoraria for serving as a speaker for Ego Pharmaceuticals and Pierre Fabre. Andrew G. Bushmakin, Pinaki Biswas, Claire Feeney, Hernan Valdez, Andrew J. Thorpe, Gary Chan, Joseph C. Cappelleri, Marco DiBonaventura, and Daniela E. Myers are employees and shareholders of Pfizer Inc. Ricardo Rojo is a former employee and current shareholder of Pfizer Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All study documents and procedures were approved by the appropriate institutional review boards\/ethics committees at each study site. The study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization Good Clinical Practice Guidelines. All local regulatory requirements were followed. This research was approved by institutional review boards or ethics committees at each study site. An internal review committee monitored the safety of patients throughout the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See  for more information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Andrew G. Bushmakin, Joseph C. Cappelleri, and Daniela E. Myers contributed to study concept and design. Andrew G. Bushmakin and Joseph C. Cappelleri conducted the statistical analysis of the data. Gil Yosipovitch, Melinda J. Gooderham, Sonja St\u00e4nder, Luz Fonacier, Jacek C. Szepietowski, Mette Deleuran, Giampiero Girolomoni, John C. Su, Andrew G. Bushmakin, Joseph C. Cappelleri, Claire Feeney, Gary Chan, Andrew J. Thorpe, Hernan Valdez, Pinaki Biswas, Ricardo Rojo, Marco DiBonaventura, and Daniela E. Myers interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}